Bio-Rad (BIO) Q4 2025 Earnings Call Transcript

Today, we will review the fourth quarter and full year 2025 financial results and provide an update on key business trends ...
The National Law Review

Bio-Rad Whistleblower Retains Most of his Record Whistleblower Retaliation Verdict on Appeal

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Bio-Rad outlines 2026 margin expansion and 0.5%-1.5% revenue growth guidance amid operational improvements

Q4 2025 Management View Jonathan DiVincenzo, President & COO, stated that Bio-Rad delivered results within revised guidance ...
Morningstar

This Undervalued Stock Offers Investors a Rare Combination

Bio-Rad Laboratories BIO is something of a rarity: a small-cap company with a wide economic moat. The company develops products and solutions for the clinical diagnostics and life sciences industries, ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2025 earnings call transcript

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2025 Earnings Call Transcript February 12, 2026 Bio-Rad Laboratories, Inc. misses on earnings expectations. Reported EPS is $2.51 EPS, expectations were $2.57.

Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript

Bio-Rad Laboratories, Inc. ( BIO) Q4 2025 Earnings Call February 12, 2026 5:00 PM EST Good day, everyone, and welcome to the Bio-Rad Fourth Quarter and Full Year 2025 Results Conference Call. At this ...